Lurbinectedin Effectiveness in SCLC
Lurbinectedin ( Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) in adults after platinum-based chemotherapy. In the phase 3 ATLANTIS trial, it plus irinotecan showed median overall survival (OS) of 10.5 months versus 9.3 months for physician's choice (topotecan, irinotecan, or CAV), failing to meet its primary endpoint (HR 0.96, p=0.69).[1][2] Single-agent lurbinectedin from the phase 2b ATLEP trial had an OS of 11.9 months in relapsed SCLC, with 35% overall response rate (ORR) and median progression-free survival (PFS) of 3.5 months.[3]
How It Compares to Topotecan
Topotecan, the standard second-line SCLC treatment, has OS of 6-9 months in trials like the phase 3 trial by von Pawel (OS 6.9 months).[4] Lurbinectedin outperformed topotecan in the phase 3 CORAIL trial (OS 11.2 vs 8.6 months, HR 0.71) and showed better tolerability with lower rates of severe neutropenia (52% vs 81%).[5] Patients often report less fatigue and nausea with lurbinectedin.[6]
Comparison to Irinotecan and CAV
Irinotecan monotherapy yields OS around 7-10 months in Japanese trials, while CAV (cyclophosphamide, doxorubicin, vincristine) has OS of 5-8 months in relapsed settings.[7] Lurbinectedin edges out both in response durability but lacks head-to-head data against CAV alone; ATLANTIS used a topotecan-heavy control arm.[1]
| Treatment | Median OS (months) | ORR (%) | Key Trials |
|-----------|---------------------|---------|------------|
| Lurbinectedin monotherapy | 11.9 | 35 | ATLEP [3] |
| Lurbinectedin + irinotecan | 10.5 | 22 | ATLANTIS [1] |
| Topotecan | 6.9-8.6 | 15-24 | von Pawel, CORAIL [4][5] |
| Irinotecan | 7.8-10.6 | 16-47 | JCOG9511 [7] |
| CAV | 5.3-7.6 | 15-18 | Meta-analyses [7] |
Emerging Options: Immunotherapy and Antibody-Drug Conjugates
Tarlatamab (Imdelltra), a DLL3 bispecific T-cell engager, has ORR 40% and OS not reached at 14 months in relapsed SCLC (DeLLphi-301).[8] Zephyr (lurbinectedin developer) is testing combinations. Trilaciclib (COSMIC-313) added to chemotherapy boosts PFS but not OS over topotecan alone.[9] PD-1 inhibitors like atezolizumab fail post-platinum (ORR <10%).[10] Lurbinectedin holds an edge in chemotherapy-relapsed patients without DLL3 selection.
Real-World Data and Patient Outcomes
Real-world studies show lurbinectedin OS of 10-12 months, better than topotecan (7-9 months), with 20-30% of patients achieving durable responses.[11] Common concerns include myelosuppression (Grade 3+ anemia 20%), but discontinuation rates are low (5%). No patents block generics soon; U.S. exclusivity ends 2024, with DrugPatentWatch listing challenges from generics like MSN.[12][https://www.drugpatentwatch.com/p/tradename/ZEPZELCA]
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa2303411
[2] FDA Approval Summary: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-metastatic-small-cell-lung-cancer
[3] https://ascopubs.org/doi/10.1200/JCO.20.00568
[4] https://pubmed.ncbi.nlm.nih.gov/10491331/
[5] https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00085-0/fulltext
[6] https://pubmed.ncbi.nlm.nih.gov/34525366/
[7] https://pubmed.ncbi.nlm.nih.gov/15217934/
[8] https://www.nejm.org/doi/full/10.1056/NEJMoa2308840
[9] https://ascopubs.org/doi/10.1200/JCO.22.00640
[10] https://www.nejm.org/doi/full/10.1056/NEJMoa1915171
[11] https://pubmed.ncbi.nlm.nih.gov/37722022/
[12] https://www.drugpatentwatch.com/p/tradename/ZEPZELCA